Temsirolimus, an inhibitor of mammalian target of rapamycin kinase, has anti-proliferative and anti-angiogenic properties. Encouraging results were seen in phase I and II studies of temsirolimus ...

Sigmart Europe has approved temsirolimus injection (Torisel); Japan has approved a new dosing regimen for ceftriaxone injection (Rocephin) and an expanded indication for nicorandil injection ...

This phase I study was conducted to determine the maximum tolerated dose of temsirolimus and sunitinib when given in combination to patients with advanced RCC. The study population consisted of ...